Hepatocellular carcinoma in a long-term survivor of acute lymphocytic leukemia.
Hepatocellular carcinoma (HCC) occurred in a 28-year-old woman treated for acute lymphocytic leukemia (ALL) with methotrexate (MTX) and 6-mercaptopurine (6-MP), off all therapy for 15 years, who was also heterozygous for alpha-1 antitrypsin (alpha-1 AT) deficiency. MTXD is responsible for the development of HCC in this patient. The literature concerning the incidence of HCC in patients treated with MTX and 6-MP and in alpha-1 antitrypsin deficiencies is reviewed.
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000032:analysis / Q000139:chemically induced* / Q000473:pathology; D005260:Female; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy / Q000473:pathology*; D008103:Liver Cirrhosis / Q000139:chemically induced / Q000150:complications; D008113:Liver Neoplasms / Q000032:analysis / Q000139:chemically induced* / Q000473:pathology; D015122:Mercaptopurine / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects*; D009363:Neoplasm Proteins / Q000032:analysis; D009378:Neoplasms, Multiple Primary / Q000473:pathology*; D000515:alpha 1-Antitrypsin / Q000032:analysis; D000509:alpha-Fetoproteins / Q000032:analysis
D009363:Neoplasm Proteins; D000515:alpha 1-Antitrypsin; D000509:alpha-Fetoproteins; D015122:Mercaptopurine; D008727:Methotrexate